355 related articles for article (PubMed ID: 32015043)
21. Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
Pfaller MA; Chaturvedi V; Diekema DJ; Ghannoum MA; Holliday NM; Killian SB; Knapp CC; Messer SA; Miskou A; Ramani R
Diagn Microbiol Infect Dis; 2012 Aug; 73(4):365-8. PubMed ID: 22726528
[TBL] [Abstract][Full Text] [Related]
22. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
[TBL] [Abstract][Full Text] [Related]
23. APX001A
Arendrup MC; Chowdhary A; Astvad KMT; Jørgensen KM
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30104264
[TBL] [Abstract][Full Text] [Related]
24. Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method.
Pfaller MA; Espinel-Ingroff A; Bustamante B; Canton E; Diekema DJ; Fothergill A; Fuller J; Gonzalez GM; Guarro J; Lass-Flörl C; Lockhart SR; Martin-Mazuelos E; Meis JF; Ostrosky-Zeichner L; Pelaez T; St-Germain G; Turnidge J
Antimicrob Agents Chemother; 2014; 58(2):916-22. PubMed ID: 24277027
[TBL] [Abstract][Full Text] [Related]
25. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.
Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Jones RN; Turnidge J; Diekema DJ
J Clin Microbiol; 2010 Jan; 48(1):52-6. PubMed ID: 19923478
[TBL] [Abstract][Full Text] [Related]
26. In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae.
Tóth Z; Forgács L; Locke JB; Kardos G; Nagy F; Kovács R; Szekely A; Borman AM; Majoros L
J Antimicrob Chemother; 2019 Dec; 74(12):3505-3510. PubMed ID: 31539426
[TBL] [Abstract][Full Text] [Related]
27. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Two Commercial Broth Microdilution Methods Using Different Interpretive Criteria for the Detection of Molecular Mechanisms of Acquired Azole and Echinocandin Resistance in Four Common
Lim HJ; Shin JH; Kim MN; Yong D; Byun SA; Choi MJ; Lee SY; Won EJ; Kee SJ; Kim SH; Shin MG
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32900684
[TBL] [Abstract][Full Text] [Related]
29. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007).
Messer SA; Moet GJ; Kirby JT; Jones RN
J Clin Microbiol; 2009 Jun; 47(6):1942-6. PubMed ID: 19386851
[TBL] [Abstract][Full Text] [Related]
30. Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates.
Eschenauer GA; Nguyen MH; Shoham S; Vazquez JA; Morris AJ; Pasculle WA; Kubin CJ; Klinker KP; Carver PL; Hanson KE; Chen S; Lam SW; Potoski BA; Clarke LG; Shields RK; Clancy CJ
Antimicrob Agents Chemother; 2014; 58(4):1897-906. PubMed ID: 24395235
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis and Candida glabrata.
Carvalhaes CG; Rhomberg PR; Pfaller MA; Locke JB; Castanheira M
Mycoses; 2022 Nov; 65(11):1040-1044. PubMed ID: 35778886
[TBL] [Abstract][Full Text] [Related]
32. Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?
Espinel-Ingroff A; Arendrup MC; Pfaller MA; Bonfietti LX; Bustamante B; Canton E; Chryssanthou E; Cuenca-Estrella M; Dannaoui E; Fothergill A; Fuller J; Gaustad P; Gonzalez GM; Guarro J; Lass-Flörl C; Lockhart SR; Meis JF; Moore CB; Ostrosky-Zeichner L; Pelaez T; Pukinskas SR; St-Germain G; Szeszs MW; Turnidge J
Antimicrob Agents Chemother; 2013 Dec; 57(12):5836-42. PubMed ID: 24018263
[TBL] [Abstract][Full Text] [Related]
33. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections.
Castanheira M; Messer SA; Jones RN; Farrell DJ; Pfaller MA
Int J Antimicrob Agents; 2014 Oct; 44(4):320-6. PubMed ID: 25129315
[TBL] [Abstract][Full Text] [Related]
34. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).
Pfaller MA; Messer SA; Moet GJ; Jones RN; Castanheira M
Int J Antimicrob Agents; 2011 Jul; 38(1):65-9. PubMed ID: 21514797
[TBL] [Abstract][Full Text] [Related]
35. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
[TBL] [Abstract][Full Text] [Related]
36. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species.
Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Moet GJ; Jones RN
J Clin Microbiol; 2010 May; 48(5):1592-9. PubMed ID: 20335424
[TBL] [Abstract][Full Text] [Related]
37. In vitro potency and fungicidal activity of CD101, a novel echinocandin, against recent clinical isolates of Candida spp.
Hall D; Bonifas R; Stapert L; Thwaites M; Shinabarger DL; Pillar CM
Diagn Microbiol Infect Dis; 2017 Nov; 89(3):205-211. PubMed ID: 28826987
[TBL] [Abstract][Full Text] [Related]
38. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
Pfaller MA; Diekema DJ; Andes D; Arendrup MC; Brown SD; Lockhart SR; Motyl M; Perlin DS;
Drug Resist Updat; 2011 Jun; 14(3):164-76. PubMed ID: 21353623
[TBL] [Abstract][Full Text] [Related]
39. Echinocandin antifungal drugs in fungal infections: a comparison.
Chen SC; Slavin MA; Sorrell TC
Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
[TBL] [Abstract][Full Text] [Related]
40. Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method.
Espinel-Ingroff A; Alvarez-Fernandez M; Cantón E; Carver PL; Chen SC; Eschenauer G; Getsinger DL; Gonzalez GM; Govender NP; Grancini A; Hanson KE; Kidd SE; Klinker K; Kubin CJ; Kus JV; Lockhart SR; Meletiadis J; Morris AJ; Pelaez T; Quindós G; Rodriguez-Iglesias M; Sánchez-Reus F; Shoham S; Wengenack NL; Borrell Solé N; Echeverria J; Esperalba J; Gómez-G de la Pedrosa E; García García I; Linares MJ; Marco F; Merino P; Pemán J; Pérez Del Molino L; Roselló Mayans E; Rubio Calvo C; Ruiz Pérez de Pipaon M; Yagüe G; Garcia-Effron G; Guinea J; Perlin DS; Sanguinetti M; Shields R; Turnidge J
Antimicrob Agents Chemother; 2015 Nov; 59(11):6725-32. PubMed ID: 26282428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
